biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by jdstoxon Jun 19, 2020 9:14am

181 Views

Post# 31168569

RE:RE:RE:The 10% Edison Conjecture

Well now, there ya go, md.

There are lots of valuations that could be worked out, and competently defended.

If xB3-001 works then it could bring in billions per year. Implicit in that is that because xB3 can transport any number of additional drugs across the BBB, then Bioasis is almost impossible to valuate.

However difficult it is to valuate now, I'm very interested to see how the market goes about it if we have successful phase 1b and phase 2 trials.

I posted about financing models and possibilities 2 weeks ago or so. Multiple scenarios. All there. Maybe we could discuss it all.

jdstox

Bullboard Posts

5 steps to mastering risk management in the stock market